Forecast Insight: Dyslipidemia - Genericization And Negative Trial Data Drive Market Shrinkage

By Author: Manjula Menon
Total Articles: 1486
Comment this article

The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep

genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as

well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.

Scope of this report

Description of the competitive landscape in antidyslipidemics across seven major markets with market definition and

overview.

Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy,

Spain, UK and Japan.

Analysis of major events and brand dynamics affecting the antidyslipidemics market.

Research and analysis highlights

Some 40% of the entire seven major market antidyslipidemic market is commanded by Lipitor, the gold standard

therapy and highest selling agent among statins and antidyslipidemics in general. This will change dramatically after

the loss of its patent protection in 2010/2011, reducing Lipitor's market share to 9% only by 2017.

The ...
... top 10 brands accounted for 81% of the market in 2007; the top revenue generating agents include Lipitor,

Vytorin, Crestor, Zetia and Tricor. Over the forecast period the share of the brands in the antidyslipidemic market is

expected to fall due to the further genericization.

The recent ENHANCE trial results have added to the distressing effects of genericization, while at the same time

curbing the sales of Zetia and Vytorin, and further undermining confidence in the surrogate markers of

atherosclerosis. This event is likely to make the ever-stricter process of approval for new agents even harder.

Key reasons to read this report

Quantify the future size and understand the background of the antidyslipidemic market

Understand the commercial landscape in terms of new product potential

Understand the barriers to uptake for novel antidyslipidemics

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=83037

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Bharat Book Bureau is the leading market research information aggregator which provides reports, company profiles,

newsletters, country info. and online databases for the past twenty years to corporate, consulting firms, academic

institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic

information tools to the executives, business analysts, and knowledge managers that will help them to probe into and

support critical, timely business decisions and strategies.It helps global companies to know different market before

starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for

the business intelligence information requirements.